Medical Policy
Implantable Cardioverter Defibrillator

Table of Contents
• Policy: Commercial  • Coding Information  • Information Pertaining to All Policies
• Policy: Medicare  • Description  • References
• Authorization Information  • Policy History

Policy Number: 070
BCBSA Reference Number: 7.01.44 (For Plan internal use only)

Related Policies
• Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure, #101
• Wearable Cardioverter Defibrillators, #042

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Adults
The use of the automatic implantable cardioverter defibrillator (ICD) may be considered MEDICALLY NECESSARY in individuals who meet the following criteria:

Primary Prevention
• Ischemic cardiomyopathy with New York Heart Association (NYHA) functional Class II or Class III symptoms, a history of myocardial infarction at least 40 days before ICD treatment and left-ventricular ejection fraction of 35% or less; OR
• Ischemic cardiomyopathy (IDCM) with NYHA functional Class I symptoms, a history of myocardial infarction at least 40 days before ICD treatment, and left ventricular ejection fraction of 30% or less; OR
• Non-ischemic dilated cardiomyopathy (NIDCM) and left ventricular ejection fraction of 35% or less, after reversible causes have been excluded, and the response to optimal medical therapy has been adequately determined; OR
• Hypertrophic cardiomyopathy (HCM) with 1 or more major risk factors for sudden cardiac death (history of premature HCM-related sudden death in 1 or more first-degree relatives younger than 50 years; left ventricular hypertrophy greater than 30 mm; 1 or more runs of non-sustained ventricular tachycardia at heart rates of 120 beats per minute or greater on 24-hour Holter monitoring; prior unexplained syncope inconsistent with neurocardiogenic origin) and judged to be at high risk for sudden cardiac death by a physician experienced in the care of individuals with HCM.
• Diagnosis of any one of the following cardiac ion channelopathies* and considered to be at high risk for sudden cardiac death:
o congenital long QT syndrome; OR
o Brugada syndrome; OR
o short QT syndrome; OR
o catecholaminergic polymorphic ventricular tachycardia.

- Diagnosis of cardiac sarcoid and considered to be at high risk for sudden cardiac death.

**Secondary Prevention**
- Individuals with a history of a life-threatening clinical event associated with ventricular arrhythmic events such as sustained ventricular tachyarrhythmia, after reversible causes (eg, acute ischemia) have been excluded.

The use of the ICD is considered **INVESTIGATIONAL** for primary prevention individuals who meet the following:
- Have had an acute myocardial infarction (i.e., less than 40 days before ICD treatment); OR
- Have NYHA Class IV congestive heart failure (unless patient is eligible to receive a combination cardiac resynchronization therapy ICD device); OR
- Have had cardiac revascularization procedure in the past 3 months (coronary artery bypass graft [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) or are candidates for a cardiac revascularization procedure; OR
- Have non-cardiac disease that would be associated with life expectancy less than 1 year.

The use of the ICD for secondary prevention is considered **INVESTIGATIONAL** for individuals who do not meet the criteria for secondary prevention.

**Pediatrics**
The use of the ICD may be considered **MEDICALLY NECESSARY** in pediatric individuals who meet any of the following criteria:
- Survivors of cardiac arrest, after reversible causes have been excluded; OR
- Symptomatic, sustained ventricular tachycardia in association with congenital heart disease in individuals who have undergone hemodynamic and electrophysiologic evaluation, OR
- Congenital heart disease with recurrent syncope of undetermined origin in the presence of either ventricular dysfunction or inducible ventricular arrhythmias.
- Hypertrophic cardiomyopathy (HCM) with 1 or more major risk factors for sudden cardiac death (history of premature HCM-related sudden death in 1 or more first-degree relatives younger than 50 years; massive left ventricular hypertrophy based on age-specific norms; prior unexplained syncope inconsistent with neurocardiogenic origin) and judged to be at high risk for sudden cardiac death by a physician experienced in the care of individuals with HCM.
- Diagnosis of any one of the following cardiac ion channelopathies and considered to be at high risk for sudden cardiac death:
  o congenital long QT syndrome; OR
  o Brugada syndrome; OR
  o short QT syndrome; OR
  o catecholaminergic polymorphic ventricular tachycardia.

The use of the ICD is considered **INVESTIGATIONAL** for all other indications in pediatric patients.

**Subcutaneous Implantable Cardioverter Defibrillator**
The use of a subcutaneous ICD may be considered **MEDICALLY NECESSARY** for adults or pediatric individuals who have an indication for ICD implantation for primary or secondary prevention for any of the above reasons and meet all of the following criteria:
- Have a contraindication to a transvenous ICD due to one or more of the following: (1) lack of adequate vascular access; (2) compelling reason to preserve existing vascular access (ie, need for chronic dialysis; younger individual with anticipated long-term need for ICD therapy); or (3) history of need for explantation of a transvenous ICD due to a complication, with ongoing need for ICD therapy.
• Have no indication for antibradycardia pacing; **AND**
• Do not have ventricular arrhythmias that are known or anticipated to respond to antitachycardia pacing.

The use of a subcutaneous ICD is considered INVESTIGATIONAL for individuals who do not meet the criteria outlined above.

**Criteria for ICD Implantation in Individuals with Cardiac Ion Channelopathies**

Individuals with cardiac ion channelopathies may have a history of a life-threatening clinical event associated with ventricular arrhythmic events such as sustained ventricular tachyarrhythmia, after reversible causes, in which case they should be considered for ICD implantation for secondary prevention, even if they do not meet criteria for primary prevention.

Criteria for ICD placement in individuals with cardiac ion channelopathies derive from results of clinical input, a 2013 consensus statement from the HRS, European Heart Rhythm Association (EHRA), and the Asia-Pacific Heart Rhythm Society on the diagnosis and management of individuals with inherited primary arrhythmia syndromes (Priori et al [2013]), 2017 guidelines from ACC, AHA, and HRS on the management of heart failure (Al-Khatib et al [2017]), and a report from the HRS and EHRA's Second Consensus Conference on Brugada syndrome.

Indications for consideration for ICD placement for each cardiac ion channelopathy are as follows:

- **Long QT syndrome (LQTS):**
  - Individuals with a diagnosis of LQTS who are survivors of cardiac arrest
  - Individuals with a diagnosis of LQTS who experience recurrent syncopal events while on β-blocker therapy.

- **Brugada syndrome (BrS):**
  - Individuals with a diagnosis of BrS who are survivors of cardiac arrest
  - Individuals with a diagnosis of BrS who have documented spontaneous sustained ventricular tachycardia (VT) with or without syncope
  - Individuals with a spontaneous diagnostic type 1 electrocardiogram (ECG) who have a history of syncope, seizure, or nocturnal agonal respiration judged to be likely caused by ventricular arrhythmias (after noncardiac causes have been ruled out)
  - Individuals with a diagnosis of BrS who develop ventricular fibrillation during programmed electrical stimulation.

- **Catecholaminergic polymorphic ventricular tachycardia (CPVT):**
  - Individuals with a diagnosis of CPVT who are survivors of cardiac arrest
  - Individuals with a diagnosis of CPVT who experience recurrent syncope or polymorphic/bidirectional VT despite optimal medical management, and/or left cardiac sympathetic denervation.

- **Short QT syndrome (SQTS):**
  - Individuals with a diagnosis of SQTS who are survivors of cardiac arrest
  - Individuals with a diagnosis of SQTS who are symptomatic and have documented spontaneous VT with or without syncope
  - Individuals with a diagnosis of SQTS or are asymptomatic or symptomatic and have a family history of sudden cardiac death.

**Criteria for Implantable Cardioverter Defibrillator Implantation in Individuals with Cardiac Sarcoid**

Criteria for ICD placement in individuals with cardiac sarcoid derive from a 2014 consensus statement from the Heart Rhythm Society (HRS) and 2017 joint guidelines from the American Heart Association, American College of Cardiology, and HRS.

Indications for consideration of ICD placement in individuals diagnosed with cardiac sarcoid are as follows:
• Spontaneous sustained ventricular arrhythmias, including prior cardiac arrest, if meaningful survival of greater than 1 year is expected;
• LVEF 35% or less, despite optimal medical therapy and a period of immunosuppression (if there is active inflammation), if meaningful survival of greater than 1 year is expected;
• LVEF greater than 35%, if meaningful survival of greater than 1 year is expected; **AND**
  o syncpe or near-syncpe, felt to be arrhythmic in etiology **OR**
  o evidence of myocardial scar by cardiac magnetic resonance imaging (MRI) or positron emission tomographic (PET) scan **OR**
  o Inducible sustained ventricular arrhythmias (>30 seconds of monomorphic VT or polymorphic VT) or clinically relevant ventricular fibrillation
• An indication for permanent pacemaker implantation.

**Prior Authorization Information**

**Inpatient**
- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**
- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

<table>
<thead>
<tr>
<th>Commercial Managed Care (HMO and POS)</th>
<th>Prior authorization is <strong>not required</strong>.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
</tbody>
</table>

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO and Indemnity:**

**CPT Codes**

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>33216</td>
<td>Insertion of transvenous electrode; single chamber (one electrode) permanent pacemaker or single chamber pacing cardioverter-defibrillator</td>
</tr>
<tr>
<td>33217</td>
<td>Dual chamber (two electrodes) permanent pacemaker or dual chamber pacing cardioverter-defibrillator</td>
</tr>
<tr>
<td>33249</td>
<td>Insertion or replacement of permanent pacing cardioverter-defibrillator system with transvenous lead(s), single or dual chamber</td>
</tr>
<tr>
<td>33270</td>
<td>Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed</td>
</tr>
<tr>
<td>33271</td>
<td>Insertion of subcutaneous implantable defibrillator electrode</td>
</tr>
</tbody>
</table>
HCPCS Codes

<table>
<thead>
<tr>
<th>HCPCS codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1721</td>
<td>Cardioverter-defibrillator, dual chamber (implantable)</td>
</tr>
<tr>
<td>C1722</td>
<td>Cardioverter-defibrillator, single chamber (implantable)</td>
</tr>
<tr>
<td>C1882</td>
<td>Cardioverter-defibrillator, other than single or dual chamber (implantable)</td>
</tr>
</tbody>
</table>

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT and/or HCPCS codes above if medical necessity criteria are met:

ICD-10-CM Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM diagnosis codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D86.85</td>
<td>Sarcoid myocarditis</td>
</tr>
<tr>
<td>D86.89</td>
<td>Sarcoidosis of other sites</td>
</tr>
<tr>
<td>I25.5</td>
<td>Ischemic cardiomyopathy</td>
</tr>
<tr>
<td>I25.6</td>
<td>Silent myocardial ischemia</td>
</tr>
<tr>
<td>I25.89</td>
<td>Other forms of chronic ischemic heart disease</td>
</tr>
<tr>
<td>I25.9</td>
<td>Chronic ischemic heart disease, unspecified</td>
</tr>
<tr>
<td>I42.1</td>
<td>Obstructive hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>I42.2</td>
<td>Other hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>I42.0</td>
<td>Dilated cardiomyopathy</td>
</tr>
<tr>
<td>I42.5</td>
<td>Other restrictive cardiomyopathy</td>
</tr>
<tr>
<td>I45.81</td>
<td>Long QT syndrome</td>
</tr>
<tr>
<td>I45.89</td>
<td>Other specified conduction disorders</td>
</tr>
<tr>
<td>I46.2</td>
<td>Cardiac arrest due to underlying cardiac condition</td>
</tr>
<tr>
<td>I46.8</td>
<td>Cardiac arrest due to other underlying condition</td>
</tr>
<tr>
<td>I46.9</td>
<td>Cardiac arrest, cause unspecified</td>
</tr>
<tr>
<td>I47.0</td>
<td>Re-entry ventricular arrhythmia</td>
</tr>
<tr>
<td>I47.20</td>
<td>Ventricular tachycardia, unspecified</td>
</tr>
<tr>
<td>I47.21</td>
<td>Torsades de pointes</td>
</tr>
<tr>
<td>I47.29</td>
<td>Other ventricular tachycardia</td>
</tr>
<tr>
<td>I49.01</td>
<td>Ventricular fibrillation</td>
</tr>
<tr>
<td>I49.8</td>
<td>Other specified cardiac arrhythmias</td>
</tr>
<tr>
<td>I49.9</td>
<td>Cardiac arrhythmia, unspecified</td>
</tr>
<tr>
<td>Q24.8</td>
<td>Other specified congenital malformations of heart</td>
</tr>
<tr>
<td>Z86.74</td>
<td>Personal history of sudden cardiac arrest</td>
</tr>
</tbody>
</table>

Description

**Ventricular Arrhythmia and Sudden Cardiac Death**

The risk of ventricular arrhythmia and sudden cardiac death (SCD) may be significantly increased in various cardiac conditions such as ischemic cardiomyopathy, particularly when associated with reduced left ventricular ejection fraction (LVEF) and prior myocardial infarction (MI); nonischemic dilated cardiomyopathy with reduced LVEF; hypertrophic cardiomyopathy and additional risk factors; congenital heart disease, particularly with recurrent syncpe; and cardiac ion channelopathies.

Treatment

Implantable cardioverter defibrillators (ICDs) monitor a patient's heart rate, recognize ventricular fibrillation or ventricular tachycardia (VT), and deliver an electric shock to terminate these arrhythmias to reduce the risk of SCD. Indications for ICD placement can be broadly subdivided into (1) secondary prevention, ie, use
in patients who have experienced a potentially life-threatening episode of VT (near SCD); and (2) primary prevention, ie, use in patients who are considered at high risk for SCD but who have not yet experienced life-threatening VT or ventricular fibrillation.

The standard ICD placement surgery involves placement of a generator in the subcutaneous tissue of the chest wall. Transvenous leads are attached to the generator and threaded intravenously into the endocardium. The leads sense and transmit information on cardiac rhythm to the generator, which analyzes the rhythm information and produces an electrical ventricular fibrillation shock when a malignant arrhythmia is recognized.

A subcutaneous ICD (S-ICD) has been developed. It does not use transvenous leads and thus avoids the need for venous access and complications associated with the insertion of venous leads. Rather, the S-ICD uses a subcutaneous electrode implanted adjacent to the left sternum. The electrodes sense the cardiac rhythm and deliver countershocks through the subcutaneous tissue of the chest wall.

Several automatic ICDs have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval (PMA) process. The FDA labeled indications generally include patients who have experienced life-threatening VT associated with cardiac arrest or VT associated with hemodynamic compromise and resistance to pharmacologic treatment. Also, devices typically have approval in the secondary prevention setting for patients with previous MI and reduced ejection fraction.

**Summary**

**Description**

An implantable cardioverter defibrillator (ICD) is a device designed to monitor a patient's heart rate, recognize ventricular fibrillation or ventricular tachycardia, and deliver an electric shock to terminate these arrhythmias to reduce the risk of sudden death. A subcutaneous ICD (S-ICD), which lacks transvenous leads, is intended to reduce lead-related complications.

**Summary of Evidence**

**Transvenous Implantable Cardioverter Defibrillators**

For individuals who have a high risk of sudden cardiac death (SCD) due to ischemic or nonischemic cardiomyopathy in adulthood who receive transvenous implantable cardioverter defibrillator (T-ICD) placement for primary prevention, the evidence includes multiple well-designed and well-conducted randomized controlled trials (RCTs) as well as systematic reviews of these trials. Relevant outcomes are overall survival (OS), morbid events, quality of life, and treatment-related mortality and morbidity. Multiple well-done RCTs have shown a benefit in overall mortality for patients with ischemic cardiomyopathy and reduced ejection fraction. Randomized controlled trials assessing early implantable cardioverter defibrillator (ICD) use following recent myocardial infarction (MI) did not support a benefit for immediate versus delayed implantation for at least 40 days. For nonischemic cardiomyopathy (NICM), there are less clinical trial data, but pooled estimates of available evidence from RCTs enrolling patients with NICM and from subgroup analyses of RCTs with mixed populations have supported a survival benefit for this group. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a high risk of SCD due to hypertrophic cardiomyopathy (HCM) in adulthood who receive T-ICD placement for primary prevention, the evidence includes several large registry studies. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. In these studies, the annual rate of appropriate ICD discharge ranged from 3.6% to 5.3%. Given the long-term high risk of SCD in patients with HCM, with the assumption that appropriate shocks are life-saving, these studies are considered adequate evidence to support the use of T-ICDs in patients with HCM. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a high risk of SCD due to an inherited cardiac ion channelopathy who receive T-ICD placement for primary prevention, the evidence includes small cohort studies of patients with these
conditions treated with ICDs. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. The limited evidence for patients with long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome has reported high rates of appropriate shocks. No studies were identified on the use of ICDs for patients with short QT syndrome. Studies comparing outcomes between patients treated and untreated with ICDs are not available. However, given the relatively small patient populations with these channelopathies and the high risk of cardiac arrhythmias, clinical trials are unlikely. Given the long-term high risk of SCD in patients with inherited cardiac ion channelopathy, with the assumption that appropriate shocks are life-saving, these studies are considered adequate evidence to support the use of T-ICDs in patients with inherited cardiac ion channelopathy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a high risk of SCD due to cardiac sarcoi due who receive T-ICD placement for primary prevention, the evidence includes small cohort studies of patients with cardiac sarcoi due treated with ICDs. The evidence is considered adequate evidence to support the use of T-ICDs in patients with cardiac sarcoi due who have not responded to optimal medical therapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have had symptomatic life-threatening sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) or who have been resuscitated from sudden cardiac arrest (secondary prevention) who receive T-ICD placement, the evidence includes multiple well-designed and well-conducted RCTs as well as systematic reviews of these trials. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. Systematic reviews of RCTs have demonstrated a 25% reduction in mortality for ICD compared with medical therapy. Analysis of data from a large administrative database has confirmed that this mortality benefit is generalizable to the clinical setting. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

**Subcutaneous Implantable Cardioverter Defibrillators**

For individuals who need an ICD and have a contraindication to a T-ICD but no indications for antibradycardia pacing and no antitachycardia pacing-responsive arrhythmias who receive subcutaneous ICD (S-ICD) placement, the evidence includes an RCT, nonrandomized studies, and case series. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. An RCT found that S-ICD significantly decreases the risk of lead-related perioperative complications compared to T-ICD. However, this study was not powered to detect differences in the rates of failed shocks or inappropriate shocks and an extension study is ongoing. Nonrandomized controlled studies have reported success rates in terminating laboratory-induced VF that are similar to T-ICD. Case series have reported high rates of detection and successful conversion of VF, and inappropriate shock rates in the range reported for T-ICD. Given the need for ICD placement in this population at risk for SCD, with the assumption that appropriate shocks are life-saving, these studies are considered adequate evidence to support the use of S-ICDs in patients with contraindication to T-ICD. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who need an ICD and have no indications for antibradycardia pacing or antitachycardia pacing-responsive arrhythmias with no contraindication to a T-ICD, who receive S-ICD placement, the evidence includes 1 RCT, nonrandomized studies, and case series. Relevant outcomes are OS, morbid events, quality of life, and treatment-related mortality and morbidity. The Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy (PRAETORIAN) trial is the only RCT on the effect of an S-ICD with health outcomes. PRAETORIAN found that S-ICD was noninferior to T-ICD on a composite outcome of complications and inappropriate shock at 48 months (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.71 to 1.39; noninferiority margin, 1.45; p=.01 for noninferiority; p=.95 for superiority). There were more device related
complications in the T-ICD group and more inappropriate shocks in the S-ICD group, but the trial was not powered for these endpoints. There is uncertainty over the applicability and interpretation of PRAETORIAN based on the choice of a composite outcome with discordant results, unclear rationale for choice of the noninferiority margin, inadequate length of follow-up to determine rates of complications, and lack of reporting of quality of life data. Comparative observational studies are insufficient to draw conclusions on whether there are small differences in efficacy between the 2 types of devices, and reported variable adverse event rates. Ongoing studies could provide additional evidence on complications and device safety over the longer term. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/2023</td>
<td>Annual policy review. Minor editorial refinements to policy statements; intent unchanged</td>
</tr>
<tr>
<td>10/2022</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>7/2022</td>
<td>Annual policy review. References added. Policy statements unchanged.</td>
</tr>
<tr>
<td>6/2021</td>
<td>Annual policy review. Description, summary, and references updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>1/2021</td>
<td>Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.</td>
</tr>
<tr>
<td>1/2018</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>7/2017</td>
<td>Annual policy review. New references added</td>
</tr>
<tr>
<td>7/2016</td>
<td>Annual policy review. New references added</td>
</tr>
<tr>
<td>3/2016</td>
<td>Annual policy review. ICD medically necessary for patients with cardiac ion channelopathies with conditions; S-ICD medically necessary in limited situations. Effective 3/1/2016.</td>
</tr>
<tr>
<td>1/2015</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>6/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.</td>
</tr>
<tr>
<td>3/2010</td>
<td>Annual policy review. No changes to policy statements.</td>
</tr>
<tr>
<td>2/2009</td>
<td>Annual policy review. No changes to policy statements.</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:
Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
Clinical Exception Process
Medical Technology Assessment Guidelines

References


102. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHR), and the International Society for Adult Congenital Heart Disease (ISACHD). Can J Cardiol. Oct 2014; 30(10): e1-e63. PMID 25262867
103. Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of Cardiology (ACC), the American Heart Association (AHA), and the Association for European Paediatric and Congenital Cardiology (AEPC) Endorsed by the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). JACC Clin Electrophysiol. Nov 2021; 7(11): 1437-1472. PMID 34794667